|
|
[Report]
Antibody Drug Targets and Focus on Breast- & Prostate Cancer
Published: 2007/11
|
|
 |
|
|
|
|
Abstract
In this triple analysis report BioSeeker Group has analyzed three major and
intertwined areas of cancer R&D, Antibody drug target, Breast- and Prostate
cancer, which are all subjects to an extensive number of innovative drug
candidates. This extensive 380+ pages report compiles and analyzes in parallel
the progress concerning drug development and competitive situation in Antibody
drug targeting and further give an in depth analysis in two key oncology
areas; Breast- and Prostate cancer. The report will not only provide a
framework but also a careful identification and evaluation of drug candidates,
technologies and competitors.
There are currently more than 400 antibody based drugs in development for the
treatment of cancer. BioSeeker has surveyed these antibodies and identified
132 antibody drug targets, belonging to 220 antibody drugs. In all they range
from preclinical development to established therapy leaders in the market
place. In total more than 420 clinical trials are included in this analysis,
covering more than 30 different cancer indications plus diagnosis and
supportive care.
Drug targets and their associated antibodies have been analyzed by BioSeeker according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
In breast cancer we have identified 170 drug candidates in clinical stage of
development and more than 100 companies are involved in the development of
these drugs. As a treatment for breast cancer hormone modifying therapies
together with different chemotherapeutic schedules have been of highest
interest during the last years of progress. A vast amount of new clinical
research data has emerged and several new clinical trials have been iniated
and others generated new results. Protein kinase inhibitors and epothilones
have generated substantial amount of new research data in this field. But,
other strategies seem not successful and we are still waiting new information
regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III
stage of development and more than 85 companies are involved in the
development of these drugs. Two of the most successful strategies are
apoptosis inducers and cell based vaccines. Three out of 10 late stage
candidates are apoptosis inducers. Cell based vaccines has been tried for some
time but has so far failed to generate substantial improvements.
Breast and Prostate Cancer Highlights
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy
|
|
|
|
|
|
|
|
[Report]
Antibody Drug Targets and Focus on Breast- & Prostate Cancer
Published: 2007/11
|
Published by : BioSeeker Group AB  |
|
|
Price:
|
Product Code : BG58166 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
